Editas Medicine (EDIT) Reports In-Line Q3 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to Editas Medicine (EDIT) Reports In-Line Q3 EPS

Chardan Capital Markets Reiterates Buy Rating on Editas Medicine (EDIT)

November 5, 2024 4:19 PM EST

Chardan Capital Markets analyst Geulah Livshits reiterated a Buy rating and $12.00 price target on Editas Medicine (NASDAQ: EDIT).

The analyst comments "EDIT (Buy, PT $12): 3Q24 Results; Reni-cel Data at ASH; In Vivo Updates in 1Q25. On 4 November, Editas Medicine reported 3Q24 results and... More

Editas Medicine (EDIT) PT Lowered to $5 at Barclays

November 5, 2024 5:23 AM EST

Barclays analyst Gena Wang lowered the price target on Editas Medicine (NASDAQ: EDIT) to $5.00 (from $7.00) while maintaining a Equalweight rating.

The analyst comments "Key takeaways. 3Q24 PR was incremental following recent strategic update (see EDIT - Strategic update mixed, 10/22/2024). Reni-cel (EDIT-301): Mgmt. reiterated... More

Editas Medicine (EDIT) PT Lowered to $8 at Truist Securities

November 4, 2024 12:25 PM EST

Truist Securities analyst Joon Lee lowered the price target on Editas Medicine (NASDAQ: EDIT) to $8.00 (from $12.00) while maintaining a Buy rating.

The analyst comments "3Q24: No surprises on the quarter post recent announcements (our prior takes - HERE and HERE). EDIT... More